ArticleESMO open2026
Evaluating MRI response criteria in microsatellite instability-high rectal cancer treated with immune checkpoint inhibitors.
Article in ESMO open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Paradigm Shifts in Perioperative Management of Colorectal Cancer: Personalization Based on Tumor Biology, Primary Site, and Recurrence Risk, and the Evolving Role of Organ Preservation.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundImmune checkpoint inhibitors (ICIs), particularly anti-programmed cell death protein 1 (PD-1) agents, have enabled consideration of non-operative management in patients with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) rectal cancer. Standard magnetic resonance imaging (MRI) response criteria-developed for chemoradiotherapy-may not accurately reflect treatment effects with ICIs, however. PATIENTS AND
methodsWe retrospectively analyzed 14 patients with locally advanced MSI-H/dMMR rectal adenocarcinoma treated with neoadjuvant anti-PD-1 monotherapy. All patients achieved a complete pathological response. MRI assessment included T2-weighted, diffusion-weighted, and contrast-enhanced sequences. Treatment response was defined as complete pathological response by surgical pathology (proctectomy), or by endoscopic and biopsy-confirmed complete remission (watch-and-wait strategy).
resultsMRI showed distinct post-treatment patterns: split scar sign (n = 2), fibrotic response (n = 5), lesion disappearance (n = 1), and residual intermediate T2 signal (n = 6). All mucinous tumors retained T2-hyperintense residues. In select cases, fibrotic response was beyond 3 months. In two surgical cases, histological analysis revealed residual mucinous material without viable tumor cells.
conclusionsMRI response patterns after anti-PD-1 monotherapy in MSI-H/dMMR rectal cancer differ from those observed after radiochemotherapy, suggesting the need to adapt current imaging criteria for accurate response assessment and informed surgical decision making. Persistent MRI abnormalities are frequent despite complete pathological response, and warrant cautious interpretation in the ICI setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.